COMT inhibition as a potential therapeutic target among individuals with comorbid Alcohol Use Disorder and Attention-Deficit/Hyperactivity Disorder Save

Date Added
April 2nd, 2019
PRO Number
Pro00086929
Researcher
Joseph Schacht

List of Studies


Profiles_link
Keywords
ADD/ADHD, Alcohol, Drug Studies, Psychiatry
Summary

The purpose of this study is to evaluate the effects of an FDA-approved medication called tolcapone in people who have both Alcohol Use Disorder (AUD) and Attention-Deficit/Hyperactivity Disorder (ADHD). The study involves seven visits over a three to four week period, including an assessment visit and two eight-day medication periods during which participants will be assigned to take, in a double-blinded fashion, both tolcapone and a placebo (three visits during each period). During two of these visits, participants will undergo a one-hour MRI scan. Participants must not be seeking treatment for AUD or ADHD and must not be currently taking any psychotropic medications, including stimulant medications for ADHD. Compensation is available for qualified participants.

Institution
MUSC
Recruitment Contact
Zoe Brasher
(843) 792-7588
brasherz@musc.edu

A pilot human laboratory study of cannabidiol in Alcohol Use Disorder Save

Date Added
March 5th, 2019
PRO Number
Pro00086168
Researcher
Joseph Schacht

List of Studies


Profiles_link
Keywords
Alcohol, Drug Studies, Psychiatry
Summary

This study will examine the effects of Epidiolex among adults who drink alcohol heavily but who are not seeking treatment for their alcohol use. Epidiolex is an FDA-approved formulation of cannabidiol, the primary non-psychoactive constituent of cannabis. Participants in the study will be randomly assigned to take Epidiolex or placebo for 8 days. There are 3 study visits, including a day-long visit in the laboratory.

Institution
MUSC
Recruitment Contact
Katy Fuqua
(843) 792-1452
fuquama@musc.edu

Oxytocin to Enhance Alcohol Behavioral Couple Therapy Save

Date Added
November 6th, 2018
PRO Number
Pro00082233
Researcher
Julianne Hellmuth

List of Studies


Profiles_link
Keywords
Alcohol, Mental Health, Military, Psychiatry, Substance Use
Summary

This study will examine the efficacy of intranasal oxytocin versus placebo in combination with Alcohol Behavioral Couples Therapy (ABCT) to reduce alcohol use disorder severity. We will also use observational coding and neuroimaging to examine behavioral and neural mechanisms underlying treatment outcomes.

Institution
MUSC
Recruitment Contact
Alexis Adams
843-792-8187
adamsale@musc.edu

Evaluation of a Web-Based Tool for Alcohol Use Following Interpersonal Violence Save

Date Added
September 23rd, 2018
PRO Number
Pro00080368
Researcher
Christine Hahn

List of Studies

Silhouette
Keywords
Alcohol, Substance Use, Women's Health
Summary

The purpose of this study is to gather feedback to inform the development of a web-based tool that provides screening and education about alcohol use following interpersonal violence. People who have experienced sexual assault or domestic violence in the last year and drink alcohol, or are currently in treatment for alcohol use, will be asked to provide feedback about a web-based tool for alcohol use. 60-minute interviews will be conducted and will involve viewing the content of the web-based tool and providing feedback. Additionally, feedback given during interviews will be analyzed and then individuals who have used the web-based tool will complete a survey following the tool use if they report using substances.

Institution
MUSC
Recruitment Contact
Christine Hahn
843-792-0259
hahnc@musc.edu

A Proof-of-Concept Trial of N-Acetylcysteine for Adolescent Alcohol Use Disorder Save

Date Added
September 4th, 2018
PRO Number
Pro00080921
Researcher
Kevin Gray

List of Studies


Profiles_link
Keywords
Adolescents, Alcohol, Substance Use
Summary

The purpose of this study is to evaluate the efficacy of the medication N-acetylcysteine (NAC) to help young people with alcohol use disorder. NAC is an over-the-counter supplement and antioxidant that has been approved by the Food and Drug Administration (FDA) in adults and children for other uses, but has not been approved by the FDA for treatment of alcohol use disorder. All participants will receive brief alcohol counseling during the 8 weeks of medication treatment. Volunteers ages 13-20 are needed for this study.

Institution
MUSC
Recruitment Contact
Youth Collaborative Intake
843-792-9257
youth@musc.edu

Preliminary Validation of a Novel Natural Rewards fMRI Paradigm: Comparing Relative Brain Activation to Natural Rewards versus Alcohol Cues in Individuals with Alcohol Use Disorder and Social Drinkers Save

Date Added
March 6th, 2018
PRO Number
Pro00075724
Researcher
Will Mellick

List of Studies

Silhouette
Keywords
Alcohol, Brain, Mental Health
Summary

This Charleston Alcohol Research Center (ARC) pilot study seeks to provide the preliminary validation of a novel natural rewards fMRI paradigm which may be used in the development and/or evaluation of alcohol addiction medication treatments. Specifically, individuals with alcohol use disorder (AUD) and social drinkers will be recruited for a magnetic resonance imaging (MRI) study which will include magnetic resonance spectroscopy, an alcohol cue task, and this novel natural rewards paradigm which examines brain response to social reward and food. Invited participants will complete an initial screening diagnostic assessment visit at the Medical University of South Carolina, which will consist of clinical interviews with research staff, questionnaires, and labs. If still eligible, participants will be invited for a second appointment which will include additional clinical measures, questionnaires, and an MRI scan. This study is confidential and participants will be compensated for participating.

Institution
MUSC
Recruitment Contact
Will Mellick
843-792-7667
mellick@musc.edu

Altering memories that increase risk of relapse in alcohol use disorders: A translational clinical neuroscience pilot investigation of a novel pharmacological agent. Save

Date Added
February 6th, 2018
PRO Number
Pro00073523
Researcher
Michael Saladin

List of Studies


Profiles_link
Keywords
Alcohol, Drug Studies, Stage II
Summary

The proposed study will employ treatment-seeking AUD individuals who will be randomly assigned to receive either 15 mg of rapamycin (sirolimus) or placebo immediately after the first of two alcohol cue exposure sessions scheduled to occur on consecutive days. Subjective responses (i.e., craving) and physiological (heart rate & skin conductance) reactivity will be obtained before, during and after cue presentations in both sessions. The durability of any observed treatment effects will be assessed in a Follow-up session performed approximately 10 days following completion of the second session. Treatment effects on self-report measures of drinking behavior during the approximately 10 days preceding the Follow-up session will also be assessed.

Institution
MUSC
Recruitment Contact
Brittany Frasier
843-792-6984
frasibri@musc.edu

Effect of GET73 on magnetic resonance spectroscopy measures of central glutamate and GABA and alcohol cue-elicited brain activation in recently abstinent non-treatment-seeking individuals with Alcohol Use Disorder Save

Date Added
September 26th, 2017
PRO Number
Pro00069862
Researcher
Raymond Anton

List of Studies


Profiles_link
Keywords
Alcohol, Brain, Drug Studies, Substance Use
Summary

The purpose of this study is to evaluate the potential mechanism of action and the safety of GET73, a new drug under development for the reduction of craving and drinking in alcohol dependent individuals. The study involves five to six visits over a three to four week period, including one to two assessment visits and two visits during which participants will be assigned to take, in a double-blinded fashion, both GET73 and a placebo (two visits during each condition). During three of these visits, participants will undergo a one-hour MRI scan. Compensation is available for qualified participants.

Institution
MUSC
Recruitment Contact
Katy Fuqua
(843) 792-1452
fuquama@musc.edu

Imaging Framework for Testing GABAergic/glutamatergic Drugs in Bipolar Alcoholics Save

Date Added
April 4th, 2017
PRO Number
Pro00064964
Researcher
James Prisciandaro

List of Studies


Profiles_link
Keywords
Alcohol, Depression, Mental Health, Psychiatry, Substance Use
Summary

This study examines the effects of the medication gabapentin and the supplement n-acetylcysteine among individuals with Bipolar Disorder who regularly drink alcohol. Participants in this study will take gabapentin, n-acetylcysteine, and matched placebo (one at a time) for 5 days each. There are 8 study visits, including 3 MRI scans.

Institution
MUSC
Recruitment Contact
Sara Hix
843-792-0572
hixs@musc.edu

Developing an integrated exposure-based therapy for co-occurring PTSD and substance use among adolescents: Teen COPE focus groups Save

Date Added
December 6th, 2016
PRO Number
Pro00060455
Researcher
Sudie Back

List of Studies


Profiles_link
Keywords
Adolescents, Alcohol, Anxiety, Mental Health, Psychiatry, Substance Use
Summary

This study aims to conduct focus groups with adolescents and parents (30 adolescents and 30 parents) to gather feedback to help design an integrated psychological therapy for co-occurring PTSD and substance use among adolescents (Teen COPE). This information will be used to make revisions to the new Teen COPE Therapist Guide and Patient Workbook.

Institution
MUSC
Recruitment Contact
Emma Barrett
843-792-5594
barrette@musc.edu

Change_preferences

-- OR --

Create_login